{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116703","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.485217+00:00","generated_at":"2026-06-08T05:46:35.589039+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Apogee Q3 net loss $20.8M; cash $422.9M; APG777 Phase 1 dosed ahead of schedule","bullets":["Net loss $20.8M in Q3 2023 vs $19.7M in Q3 2022; R&D spend rose to $17.1M from $9.9M.","Cash $422.9M as of Sept 30, 2023; expected runway into Q4 2026 after $345M IPO in July.","Phase 1 trial of APG777 begun ahead of schedule; initial PK/safety data from healthy volunteers expected mid-2024.","Development candidate for APG808 (anti-IL-4Rα) finalized in Q4 2023; preclinical half-life up to 26 days vs 12 days for DUPIXENT.","Mark C. McKenna appointed Chairman; Matt Batters joined as General Counsel in August 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116703","json":"https://secwatch.observer/filing/0001104659-23-116703.json","markdown":"https://secwatch.observer/filing/0001104659-23-116703.md","text":"https://secwatch.observer/filing/0001104659-23-116703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/0001104659-23-116703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/tm2330055d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:46:35.589039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"795ebf5d829bb7489a78cdd9038380c25386369d","claim":"Apogee Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/0001104659-23-116703-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}